Insmed gains FDA approval for Brinsupri in bronchiectasis, while analysts see multi-billion sales potential from its expanding pipeline through 2035 ...

JPMorgan raised the firm’s price target on Insmed (INSM) to $135 from $111 and keeps an Overweight rating on the shares. The firm sees Brinsupri ...

James D. Chalmers, MBChB, PhD, explains that the ASPEN trial findings show that brensocatib reduces exacerbations, slows lung function decline at higher doses, and offers clinicians a long-awaited ...